The 2018 National Institute on Aging—Alzheimer’s Association (NIA-AA) research framework defined Alzheimer’s disease by its pathologic processes documented by biomarkers, i.e., aggregated amyloid β (Aβ), pathologic tau and neurodegeneration, rather than by clinical symptoms/signs of the disease; Alzheimer’s disease refers to positive Aβ plaques and pathologic tau deposits, whereas Alzheimer’s pathologic change, as the earlier stage, exhibits abnormal Aβ biomarkers but normal pathologic tau biomarkers [3]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.